NasdaqGM:WVEPharmaceuticals
Wave Life Sciences Obesity Proof Of Concept Sparks Focus On Pipeline Upside
Wave Life Sciences reported positive proof of concept for obesity candidate WVE-007 in Phase I, with fat loss and preservation of muscle mass.
The company is preparing a pivotal Phase II trial for WVE-007 following these early clinical results.
RNA editing candidates WVE-006 for alpha-1 antitrypsin deficiency and WVE-008 for liver disease are progressing toward key regulatory milestones.
For investors tracking NasdaqGM:WVE, these updates come with a share price of $13.85 and a very large 3...